Profiles and Reports
Profiles and Reports
Industry Profile 2016
The annual 2016 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.
Chart Pack: Value of Personalized Medicine
This chart pack provides facts and figures about the promise of personalized medicine in delivering the right treatment to the right patient at the right dose the first time through the use of molecular biomarker tests and targeted therapies.
Chart Pack: Biopharmaceuticals in Government Programs
This chart pack features key facts about prescription medicines in four major government programs—Medicare, Medicaid, the US Department of Veterans Affairs (VA), and the 340B program.
Chart Pack: Biopharmaceuticals in Perspective
This chart pack provides facts and figures about prescription medicines and their role in the health care system. Topics include medicines' impact on health and quality of life, the drug discovery and development process, health care spending, and more.
Chart Pack: Cancer Medicines – Value in Context
This chart pack provides facts and figures about the role innovative treatments play in the fight against cancer. Data and information found in this publication were drawn from a wide range of sources, including government agency reports, peer‐reviewed journals, and the Pharmaceutical Research and Manufacturers of America’s (PhRMA’s) own research and analysis. PhRMA hopes this publication provides useful context for discussions about the value of cancer medicine.
Researching Alzheimer's Medicines
Alzheimer’s disease is among the most devastating diseases anyone can face. Learn about how researchers are advancing treatment options and the challenges they face.
The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time
A new white paper by Boston Healthcare Associates examines how innovative medicines are driving significant progress in the fight against cancer. Though initial approval by the U.S. Food and Drug Administration is a tremendous milestone, ongoing research and accumulation of knowledge reveals benefits that were not able to be recognized at that time. Through use in combinations, earlier in the disease progression, use with biomarkers, and even in other disease indications, additional value emerges over time.
The U.S. biopharmaceutical industry develops medicines that save, sustain and improve lives. The industry is also well recognized as a dynamic and innovative business sector generating high-quality jobs and powering economic output and exports for the U.S. economy. This report quantifies this economic impact of the biopharmaceutical sector on the U.S. economy and jobs.
Biopharmaceutical Sector Impact on U.S. Economy
Learn how the biopharmaceutical sector impacts the U.S. economy and supports jobs.
2014 STEM Report
Continued scientific and technological innovations are critical to fostering sustained economic growth, global competitiveness, and most importantly, helping patients live longer, healthier, and more productive lives. The U.S. innovative biopharmaceutical industry is committed to building on new scientific discoveries and technological advances, relying on a workforce with education and skills in science, technology, engineering, and math (STEM).
STEM Fact Sheet
STEM is building a 21st century workforce to develop tomorrow's new medicines.
ACA Health Insurance Exchanges Breakaway Report
A new report from Breakaway Health reviews the benefit designs relating to prescription medicines and other health care items and services -- looking at deductibles, out-of-pocket maximums, cost sharing, and other factors.
Recognizing the Value of Innovation in HIV/AIDS Therapy
A new white paper from Boston Healthcare Associates takes a closer look at the remarkable advances we’ve made in the treatment of HIV/AIDS. Progress against HIV/AIDS has occurred through a series of incremental gains in knowledge and discovery, transforming what was once considered an acute fatal illness into a manageable chronic condition for those who have access to treatment.
Recognizing the Value of Innovation in Rheumatoid Arthritis
A new white paper from Boston Healthcare Associates explores the various ways in which additional clinical value has been realized over time for RA patients. As our understanding of the underlying mechanism of the disease grows, and researchers accumulate knowledge regarding the real-world use of many therapies, the treatment paradigm has shifted from aiming for symptom relief to targeting disease remission.
Innovation in the Biopharmaceutical Pipeline: A Multidimensional View
Vaccine Fact Book 2013
Vaccine research and development is lengthy and risky. From discovery to license requires 10 to 15 years. Approximately one out of 10 vaccines that enter clinical development will reach the market.
The Biopharmaceutical Pipeline: Evolving Science, Hope for Patients
Biopharmaceuticals in Medicare, Medicaid and Department of Veterans Affairs
Growth Platform For Economies Around the World
Driving State Economic Growth in the 21st Century: Advancing the Biopharmaceutical Sector
The biopharmaceutical industry contributes significantly to national, state, and local economies. Recognizing this sector’s contributions to state economies in terms of providing high‐value, high‐wage, revenue‐generating jobs, PhRMA commissioned Battelle to conduct this study to examine the extent to which state governments are targeting the industry for economic growth and development.
l Marketing & Promotion
Activities conducted as part of pharmaceutical marketing and promotion are an important part of informing consumers and healthcare professionals about new treatments. This booklet offers facts that we believe are important to consider as the value of marketing and promotion is debated.
New Medicines Approvals in 2013
In 2013, the Food and Drug Administration (FDA) approved 34 new medicines — down from a 15-year high of 44 in 2012. Of those, 27 were approved by the Center for Drug Evaluation and Research (CDER) and seven by the Center for Biologics Evaluation and Research (CBER).